OHI and DHG PHARMA have successfully upgraded their non-betalactam drug manufacturing plant to meet EU-GMP standards

Orioled Hub Institute of Pharmaceutical Technologies (OHI) has successfully collaborated with Hau Giang Pharma Joint Stock Company (DHG Pharma) to upgrade DHG Pharma’s non-betalactam drug manufacturing plant to meet EU-GMP standards. The successful project has contributed to enhancing the competitiveness of pharmaceuticals manufactured by Vietnam’s leading pharmaceutical company on the international market.

Over the past 50 years, DHG Pharma has emerged as a leading pharmaceutical company in Vietnam, renowned for its extensive distribution network and diverse product portfolio. The company’s commitment to quality and innovation has enabled it to maintain a strong market position both domestically and internationally.

In the context of global integration, Good Manufacturing Practice (GMP) according to the European Union (EU) standards is considered one of the most stringent guidelines that manufacturing plants must adhere to in order to ensure drug quality. EU-GMP certification not only helps businesses enhance their reputation but also opens up opportunities to export products to European markets and many other countries that recognize this standard.

Achieving EU-GMP certification not only opens doors to international markets but also provides domestic pharmaceutical companies with a significant competitive advantage. By enabling participation in bidding groups 1 and 2, EU-GMP certification unlocks access to a larger market share within Vietnam. According to data released by the Ministry of Health, as of August 2024, there are 283 manufacturing facilities that have achieved GMP certification nationwide. However, only about 22 facilities have achieved EU-GMP or equivalent certification (approximately 7.7%), indicating a huge market potential for pharmaceuticals when these facilities participate in drug bidding.

Obtaining EU-GMP certification is a significant challenge for domestic manufacturers, involving expertise, capital investment, and the commitment of the project team. To overcome these challenges, the partnership with a strategic partner who possesses high professional expertise in GMP, experience, and a deep understanding of the European Union’s pharmaceutical management is essential to the project’s success.

Orioled Hub Institute of Pharmaceutical Technologies (OHI) is establishing itself as a leading partner in providing EU-GMP consultancy services to Vietnam’s top pharmaceutical companies. With a team of highly experienced Vietnamese experts and a track record of successful EU-GMP assessments and re-assessments in Vietnam and companies Southeast Asia, OHI has become a trusted partner for many pharmaceutical. The successful implementation of the EU-GMP project at DHG Pharma’s Non-betalactam plant is a testament to OHI’s capabilities and dedication.

By actively supporting leading Vietnamese pharmaceutical companies in achieving EU-GMP compliance, OHI is not only contributing to the growth of Vietnam’s pharmaceutical industry but also strengthening its own brand and market position. With an ambitious goal of becoming one of the top 1,000 Forbes companies in Southeast Asia by 2035, Orioled Hub is poised to take on new challenges and achieve greater heights.